Product Description: Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide[1]. Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time[2][3].
Formula: C20H33D4NO2
References: [1]Wang X, et al. X. Synthesis of linoleoyl ethanolamide. J Oleo Sci. 2013;62(6):427-433. /[2]Lin S, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41(27):5353-5361. /[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
CAS Number: 1451194-69-6
Molecular Weight: 327.54
Research Area: Neurological Disease
Target: Cannabinoid Receptor;Isotope-Labeled Compounds
English
Deutsch
